Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non-Small Cell Lung Cancer

Submitted by ktsaganis@resea... on Tue, 09/10/2019 - 16:39

September 15, 2019, Chicago, Illinois

Please note that slides are for review only and not to be repurposed or published.

INTRODUCTION:
Dr Langer

MODULE 1:
Established Management Paradigms and Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors for Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC) — Dr Jolly

MODULE 2:
Integration of Immune Checkpoint Inhibition into the Management of Locally Advanced NSCLC — Dr Langer

MODULE 3:
Incidence, Recognition and Management of Immune-Mediated and Other Toxicities with the Use of Anti-PD-L1 Antibody Therapy for Locally Advanced Disease — Dr Patel

MODULE 4:
Ongoing and Planned Clinical Trials of Immune Checkpoint Inhibitors for Patients with Nonmetastatic NSCLC — Dr Loo

Live Poll Results
Download